secwatch.observer — SEC 8-K summary
======================================

Issuer:     RELMADA THERAPEUTICS, INC. (RLMD)
CIK:        0001553643
Form:       8-K
Filed at:   2025-09-02T23:59:59+00:00
Accession:  0001213900-25-082910
Event type: other
Sentiment:  positive
Materiality: 0.30
Item codes: 7.01
LLM model:  deepseek-v4-flash:cloud@v2

Relmada Therapeutics CMO-Urology buys 55,000 shares in open market on Aug 29, 2025
--------------------------------------------------------------------------------

- Raj S. Pruthi, MD, Chief Medical Officer-Urology, purchased 55,000 shares of RLMD common stock on August 29, 2025.
- The purchase was executed via open market transactions; no specific price disclosed in filing.
- Insider purchase may signal management confidence in the company's outlook.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1553643/000121390025082910/0001213900-25-082910-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1553643/000121390025082910/ea0255475-8k_relmada.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-082910

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer